Tetraphase Pharmaceuticals (TTPH) Earns Media Sentiment Score of 0.08

Media coverage about Tetraphase Pharmaceuticals (NASDAQ:TTPH) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.4621274777242 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

Shares of TTPH stock traded down $0.09 during trading hours on Monday, reaching $3.14. The company had a trading volume of 570,251 shares, compared to its average volume of 1,434,733. Tetraphase Pharmaceuticals has a 12 month low of $2.05 and a 12 month high of $8.75. The firm has a market capitalization of $166.65, a PE ratio of -1.19 and a beta of 2.61.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.18. The business had revenue of $2.53 million for the quarter, compared to analyst estimates of $2.26 million. Tetraphase Pharmaceuticals had a negative return on equity of 90.75% and a negative net margin of 1,187.17%. research analysts expect that Tetraphase Pharmaceuticals will post -1.58 EPS for the current year.

A number of brokerages have recently issued reports on TTPH. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. BidaskClub cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Piper Jaffray reaffirmed an “overweight” rating and set a $8.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, February 14th. BMO Capital Markets cut Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a research note on Wednesday, February 14th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $10.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $7.22.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the sale, the insider now directly owns 8,750 shares in the company, valued at $54,425. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 5.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://weekherald.com/2018/04/23/tetraphase-pharmaceuticals-ttph-earns-media-sentiment-score-of-0-08.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Insider Buying and Selling by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply